Thymic size is increased by infancy, but not pregnancy, nutritional supplementation in rural Gambian children: a randomized clinical trial.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
18 02 2019
Historique:
received: 23 10 2018
accepted: 21 01 2019
entrez: 19 2 2019
pubmed: 19 2 2019
medline: 14 11 2019
Statut: epublish

Résumé

Thymic size in early infancy predicts subsequent survival in low-income settings. The human thymus develops from early gestation, is most active in early life and is highly sensitive to malnutrition. Our objective was to test whether thymic size in infancy could be increased by maternal and/or infant nutritional supplementation. The Early Nutrition and Immune Development (ENID) Trial was a randomized 2 × 2 × 2 factorial, partially blinded trial of nutritional supplementation conducted in rural Gambia, West Africa. Pregnant women (N = 875) were randomized to four intervention groups (iron-folate (standard care), multiple micronutrients, protein energy or protein energy + multiple micronutrients at 'booking' (mean gestational age at enrolment = 13.6 weeks, range 8-20 weeks) until delivery. The iron-folate and multiple micronutrient arms were administered in tablet form and the protein energy arms as a lipid-based nutritional supplement. All intervention arms contained 60 mg iron and 400 μg folic acid per daily dose. From 24 to 52 weeks of age, infants from all groups were randomized to receive a daily lipid-based nutritional supplement, with or without additional micronutrients. Thymic size was assessed by ultrasonography at 1, 8, 24 and 52 weeks of infant age, and a volume-related thymic index calculated. Detailed data on infant growth, feeding status and morbidity were collected. A total of 724 (82.7%) mother-infant pairs completed the trial to infant age 52 weeks. Thymic size in infancy was not significantly associated with maternal supplement group at any post-natal time point. Infants who received the daily LNS with additional micronutrients had a significantly larger thymic index at 52 weeks of age (equivalent to an 8.0% increase in thymic index [95% CI 2.89, 13.4], P = 0.002). No interaction was observed between maternal and infant supplement groups. A micronutrient-fortified lipid-based supplement given in the latter half of infancy increased thymic size, a key mediator of immune function. Improving the micronutrient status of infants from populations with marginal micronutrient status may improve immune development and survival. ISRCTN registry (controlled-trials.com) Identifier: ISRCTN49285450.

Sections du résumé

BACKGROUND
Thymic size in early infancy predicts subsequent survival in low-income settings. The human thymus develops from early gestation, is most active in early life and is highly sensitive to malnutrition. Our objective was to test whether thymic size in infancy could be increased by maternal and/or infant nutritional supplementation.
METHODS
The Early Nutrition and Immune Development (ENID) Trial was a randomized 2 × 2 × 2 factorial, partially blinded trial of nutritional supplementation conducted in rural Gambia, West Africa. Pregnant women (N = 875) were randomized to four intervention groups (iron-folate (standard care), multiple micronutrients, protein energy or protein energy + multiple micronutrients at 'booking' (mean gestational age at enrolment = 13.6 weeks, range 8-20 weeks) until delivery. The iron-folate and multiple micronutrient arms were administered in tablet form and the protein energy arms as a lipid-based nutritional supplement. All intervention arms contained 60 mg iron and 400 μg folic acid per daily dose. From 24 to 52 weeks of age, infants from all groups were randomized to receive a daily lipid-based nutritional supplement, with or without additional micronutrients. Thymic size was assessed by ultrasonography at 1, 8, 24 and 52 weeks of infant age, and a volume-related thymic index calculated. Detailed data on infant growth, feeding status and morbidity were collected.
RESULTS
A total of 724 (82.7%) mother-infant pairs completed the trial to infant age 52 weeks. Thymic size in infancy was not significantly associated with maternal supplement group at any post-natal time point. Infants who received the daily LNS with additional micronutrients had a significantly larger thymic index at 52 weeks of age (equivalent to an 8.0% increase in thymic index [95% CI 2.89, 13.4], P = 0.002). No interaction was observed between maternal and infant supplement groups.
CONCLUSIONS
A micronutrient-fortified lipid-based supplement given in the latter half of infancy increased thymic size, a key mediator of immune function. Improving the micronutrient status of infants from populations with marginal micronutrient status may improve immune development and survival.
TRIAL REGISTRATION
ISRCTN registry (controlled-trials.com) Identifier: ISRCTN49285450.

Identifiants

pubmed: 30773140
doi: 10.1186/s12916-019-1264-2
pii: 10.1186/s12916-019-1264-2
pmc: PMC6378709
doi:

Substances chimiques

Micronutrients 0

Banques de données

ISRCTN
['ISRCTN49285450']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

38

Subventions

Organisme : Medical Research Council
ID : MR/P012019/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U123292701
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00026/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-A760-5QX00
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_1005/1
Pays : United Kingdom

Références

Matern Child Nutr. 2017 Jan;13(1):
pubmed: 26898720
J Pediatr. 2008 Nov;153(5):683-8, 688.e1-3
pubmed: 18589444
Sante. 1996 Jul-Aug;6(4):201-8
pubmed: 9026317
BMC Pregnancy Childbirth. 2016 Aug 30;16:253
pubmed: 27577112
Lancet. 2014 Sep 6;384(9946):857-68
pubmed: 25209487
Brain Dev. 1980;2(1):3-14
pubmed: 7416439
Am J Clin Nutr. 2009 Dec;90(6):1593-600
pubmed: 19812173
J Clin Invest. 1999 Oct;104(8):1051-9
pubmed: 10525043
Lancet. 1977 Nov 19;2(8047):1057-9
pubmed: 72960
Br J Nutr. 1999 May;81(5):405-11
pubmed: 10615213
Life Sci. 2001 Aug 24;69(14):1639-49
pubmed: 11589504
Matern Child Nutr. 2011 Oct;7(4):344-56
pubmed: 21496207
Lancet. 2013 Aug 3;382(9890):427-451
pubmed: 23746772
Br J Nutr. 1999 May;81(5):345-7
pubmed: 10615206
Lancet Glob Health. 2017 Nov;5(11):e1090-e1100
pubmed: 29025632
Paediatr Perinat Epidemiol. 2006 May;20(3):251-9
pubmed: 16629700
BMJ. 1997 Sep 27;315(7111):786-90
pubmed: 9345173
Nat Rev Immunol. 2011 May 27;11(7):489-95
pubmed: 21617694
Acta Paediatr. 2009 Jul;98(7):1168-75
pubmed: 19432828
Anal Bioanal Chem. 2013 May;405(13):4549-60
pubmed: 23462981
Int J Epidemiol. 2017 Apr 1;46(2):e13
pubmed: 26559544
Acta Paediatr. 2003 Sep;92(9):1014-20
pubmed: 14599061
Comp Biochem Physiol A Comp Physiol. 1991;98(2):235-40
pubmed: 1673889
Eur J Clin Nutr. 2005 Sep;59(9):1081-9
pubmed: 16015266
Am J Clin Nutr. 1994 Aug;60(2):274-8
pubmed: 8030607
BMC Pregnancy Childbirth. 2012 Oct 11;12:107
pubmed: 23057665
Eur Radiol. 1996;6(5):700-3
pubmed: 8934137
BMC Immunol. 2008 May 07;9:18
pubmed: 18462487
Placenta. 2014 Jan;35(1):72-4
pubmed: 24125806
Int J Epidemiol. 2014 Feb;43(1):216-23
pubmed: 24366492
Acta Paediatr. 2002;91(6):698-703
pubmed: 12162605
Pediatr Allergy Immunol. 2004 Apr;15(2):127-32
pubmed: 15059188
Am J Clin Nutr. 1990 Feb;51(2):228-32
pubmed: 2305709
Proc Nutr Soc. 2010 Nov;69(4):636-43
pubmed: 20860857

Auteurs

Sophie E Moore (SE)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia. sophie.moore@kcl.ac.uk.
Division of Women and Children's Health, King's College London, St Thomas' Hospital, 10th Floor North Wing, London, SE1 7EH, UK. sophie.moore@kcl.ac.uk.

Anthony J C Fulford (AJC)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.

Fatou Sosseh (F)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.

Patrick Nshe (P)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.

Momodou K Darboe (MK)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.

Andrew M Prentice (AM)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH